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Quinine has been increasingly utilized as a placebo in cystic fibrosis (CF) clinical trials, including those leading to FDA approval
of inhaled tobramycin, recent studies of anti-inflammatory aerosols such as glutathione, and clinical testing of hypertonic saline
aerosols to augment mucous clearance. The drug effectively masks taste of experimental therapeutics, but could also confer changes
in processes contributing to CF pathogenesis, including chloride secretion and paracellular ion permeability. In the Ussing chamber,
concentrations of quinine (1 mg/ml) anticipated in the airways of CF subjects after aerosolization led to changes in chloride transport
in Calu-3 (airway serous glandular) cell monolayers. Tissue resistance was significantly disrupted by the compound in both Calu-3
and primary airway epithelial cells in vitro. Lower doses of quinine (between 10 and 100 μg/ml) strongly inhibited the chloride
secretory mechanism that utilizes CFTR, and forskolin activated ISC was reduced by approximately 24% and 44% in the presence of
10 and 100 μg/ml quinine, respectively. Our findings indicate that quinine disrupts airway epithelial functional integrity and blocks
transepithelial chloride transport. The use of quinine as a taste-masking agent may have bioelectric effects relevant to CF trials using
aerosolized drug delivery.
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Cystic fibrosis (CF) is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR), an
integral membrane protein that governs ion transport acrossAbbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane
regulator; FBS, fetal bovine serum; HPC, human placental collagen; ISC,
short-circuit current; MEM, minimal essential media; ORCC, outwardly
rectified chloride channel; PBS, sodium phosphate-buffered isotonic saline;
TER, transepithelial electrical resistance; s, seconds; UAB, University of
Alabama at Birmingham.
⁎ Corresponding author. 1900 University Boulevard (THT 215), Birming-
ham, Alabama 35294, United States. Tel.: +1 205 934 5400; fax: +1 205 934
7593.
E-mail address: smrowe@uab.edu (S.M. Rowe).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.01.001epithelial tissues [1]. Abnormalities in CFTR structure and
function lead to hyperviscous secretions in the lungs,
pulmonary infection and progressive respiratory decline.
Life expectancy in CF has steadily increased due to cum-
ulative improvements in supportive care. Anti-inflammatory
agents and new therapies delivered by nebulization such as
recombinant human DNase, inhaled tobramycin, and
hypertonic saline have been shown to decrease CF morbidity
in randomized controlled trials [2–7]. Experimental aerosols
for CF therapy (chloride secretagogues, anti-inflammatory
agents, airway surface volume expanders, and sodium chan-
nel blockers) are in progress or envisioned within multicen-
ter, placebo controlled trials in the immediate future.
Quinine has served as a placebo in CF clinical studies,
including trials utilizing nebulized tobramycin, glutathione,ed by Elsevier B.V. All rights reserved.
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strategies [4,8–10]. The compound masks the taste of ther-
apeutic agents, presumably due to its ability to block ion
channels crucial to gustatory sensation [11]. Quinine is
known to alter the bioelectric properties of human cell types
such as bronchial epithelial cells [12]. Quinine has also been
shown to have ion transport effects in tissues including
cardiac muscle [13] and colon [14]. In the present experi-
ments, we examined whether quinine might influence bio-
electric properties of airway epithelia in a fashion that could
compromise its role as an inert placebo for CF therapeutic
drug development. We tested effects of quinine on chloride
dependent short circuit current (ISC) and epithelial resistance,
two parameters fundamental to normal lung physiology and
cystic fibrosis lung disease pathogenesis.
2. Methods
2.1. Cell culture
Calu-3 (human airway serous glandular) cells were
obtained from the American Type Culture Collection
(Manassas, VA) and propagated in minimal essential media
(MEM) with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin supplemented with non-essential
amino acids. For Ussing chamber, transepithelial electrical
resistance (TER), and immunofluorescence experiments,
polarized Calu-3 monolayers at an air–liquid interface were
grown on Costar® Transwell®-polyester membrane filters
(6.5 mm diameter, 0.4 μM pore size; Fisher Scientific,
Pittsburgh, PA) coated with human placental collagen (HPC,
Becton Dickinson, Franklin Lakes, NJ) at 5 μg/mL and
seeded at ∼1×106 cells/cm2. Apical medium was removed
at confluency (5–7 days after seeding) and filters incubated
for another 48 h to confer a polarized phenotype. Mono-
layers were studied at resistances of 800–1500 Ω across a
0.33 cm2 filter area (∼250–500 Ω cm2). All experiments
were internally controlled by utilizing direct comparisons
between cells of the same passage frequency and identical
culture conditions.
Primary human airway cells were isolated from CF sinus
tissues obtained through the University of Alabama at
Birmingham (UAB) Tissue Procurement Office and follow-
ing approval by the UAB Institutional Review Board. After
treatment with 1.5 mg/mL pronase for 24–48 h (Roche
Diagnostics, Indianapolis, IN), cells were grown as explant
cultures on Vitrogen treated Costar® Transwell® filters
(6.5 mm, 0.4 μm) using DMEM/F12 medium with sup-
plements. Cells were studied approximately 2 weeks after
plating.
2.2. Transepithelial current measurements
Calu-3 polarized monolayers were mounted in Ussing
chambers (Jim's Instruments, Iowa City, IA) in Ringers
solution on both the apical and basolateral surfaces(120 mM NaCl, 25 mM NaHCO3, 3.3 mM KH2P04,
0.83 mM K2HP04, 1.2 mM CaC12, 1.2 mM MgC12, and
10 mM D-Glucose at pH 7.4; osmolarity ∼320 mM).
Chambers and bath solutions were maintained at 37 °C with
continuous 5% CO2. An epithelial voltage clamp (Univer-
sity of Iowa Bioengineering, Iowa City, IA) was used to
measure short-circuit current (ISC) with resistance moni-
tored by 1 s, 3 mV pulses initiated every 100 s. To measure
stimulated ISC, quinine (1 mg/mL, 100 μg/mL, or 10 μg/
mL) was added to either the mucosal or serosal surface in
Ringers solution. In some experiments, the mucosal or
serosal bath was changed to a low Cl− solution (1.2 mM
NaCl, 115 mM sodium gluconate, and other components as
above) to determine the effect of a chloride secretory (low
mucosal chloride) or resorptive (low serosal chloride)
directed gradient. Forskolin (20 μM, dissolved in 20 mM
DMSO stock solution) was used to activate CFTR through
cyclic AMP, and glybenclamide (200 μM in 200 mM
DMSO stock solution) or CFTRinh −172 (20 μM in 20 mM
H2O stock solution) were used to inhibit CFTR mediated
anion transport.
2.3. Immunofluorescence studies
Calu-3 cells were grown as polarized monolayers on
12 mm tissue culture inserts coated with 5 μg/cm2 HPC.
Cells were treated with quinine, rinsed 3 times with cold
PBS, and fixed with either −20 °C methanol for 10 min or
4% formaldehyde for 30 min. Following three rinses with
cold PBS, a 1:20 dilution of goat serum (20 min at room
temperature) was used to block nonspecific protein-binding
sites. Filters were then cut from inserts and incubated for 2 h
at room temperature with primary antibody obtained from
ATCC (HB-11947) [1:100 anti-CFTR 24-1 (methanol fixed);
1:50 anti-CFTR M3A7 (Upstate) (formaldehyde fixed); or
non-immune mouse IgG (negative control)] [15]. After
washing, an additional antibody [1:100 anti-ZO1 or 5 μg/ml
non-immune rabbit IgG (negative control)] was added for 1 h
at room temperature. Antibody detection was with 1:500
dilution of anti-mouse IgG Alexa Fluor 488 or anti-rabbit
ISG Alexa Fluor 594 for 1 h at room temperature. The cells
were then washed and mounted on slides in Vectashield/
DAPI by folding the filters so that the apical surfaces were
exposed [16].
2.4. Statistical analysis
For ISC and resistance measurements, descriptive statis-
tics (mean and SEM) were reported. Statistical comparisons
utilized Student's t-tests, and were performed using Sigma-
Stat software (Jandel, CA) and/or Microsoft Excel (Seattle,
WA). All statistical tests were two-sided and were performed
at α=0.05. For statistical analysis of short-circuit current,
summary data was used to describe the specific change in ISC
compared to the stable baseline prior to drug treatment unless
otherwise expressly noted.
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3.1. Quinine alters paracellular chloride permeability of
airway epithelial monolayers
Quinine is typically aerosolized at doses of 1.25 mg/5 mL
as a taste masking agent in CF therapeutic trials [4–6,9].
Because the final concentration of quinine in the airway
surface liquid following aerosolized delivery is not known,
we tested a range of concentrations from 10–1000 μg/mL.
Higher concentrations were studied in part because hyper-
absorption of fluid has been reported in CF surface epi-
thelium and could have concentrating effects on small
molecules aerosolized to the periciliary layer. In either case, a
range of concentrations (including levels below those
anticipated in vivo, see below) were evaluated.
Ussing chamber measurements in Calu-3 cells grown as
monolayers at an air–liquid interface demonstrated augmen-
tation of chloride permeability by quinine at 1 mg/mL
(Fig. 1, Panel A). The effect was observed with either apical
or basolateral addition of compound. Inhibition of CFTR
using glybenclamide (200 μM) caused small, inconsistent
blockade (Fig. 1, Panel A), while experiments utilizing the
highly specific CFTR inhibitor CFTRinh −172 (20 μM) in
lieu of glybenclamide resulted in no inhibition of ion trans-
port (mean change +1.5 μA/cm2, n=8). Control experiments
(omitting chloride on both sides of the monolayer to removeFig. 1. Apical addition of high dose quinine to Calu-3 monolayers. Cells were grown
Ringers solution followed by 1) mucosal (M) low-Cl− solution, 2) addition of 1 mg
as in A, with mucosal and serosal low-Cl− solution (i.e. no chloride gradient) priothe chloride secretory gradient) revealed chloride depen-
dence of the change in permeability (measured as μA, Fig. 1,
Panel B; summarized in Fig. 2, Panel A). The observed
change of chloride movement in a reverse (resorptive)
chloride gradient suggested effects on paracellular (junc-
tional) pathways present in airway monolayers. Addition of
bumetanide (a blocker of basolateral chloride entry) had no
effect, further indicating a paracellular mechanism (Fig. 2,
Panel A). One mg/ml quinine resulted in a significant re-
duction of resistance over a 10 min period in Calu-3 cells
( p=0.004, Fig. 2, Panel B), although tight junction com-
plexes were not grossly disrupted under the same condi-
tions (Fig. 2, Panel C). Similar effects were also observed in
primary cultures of human airway surface epithelial cells
(Fig. 2, Panel D and E).
To evaluate the effects of high concentration quinine on
cyclic AMP mediated CFTR activity, Calu-3 cells grown as
monolayers were studied in Ringers solution followed se-
quentially by 1) mucosal low Cl−, 2) 20 μM forskolin, 3)
1 mg/mL quinine, and 4) 200 μM glybenclamide. After
stimulation of CFTR with forskolin, a mean ISC of 52 μA/
cm2 was observed, which increased modestly following ad-
dition of quinine (Fig. 3, Panels A and B). Reversal of the
gradient abrogated forskolin dependent ISC, with a further
negative deflection again observed following quinine indi-
cating dependence on the imposed chloride gradient. The
absolute magnitude of ion transport seen with quinine in aat an air–liquid interface and studied in Ussing chambers. A: Calu-3 cells in
/mL quinine, and 3) addition of 200 μM glybenclamide. B: Same experiment
r to addition of quinine.
Fig. 2. Quinine increases Cl− permeability in airway epithelia through a paracellular pathway associated with decreased epithelial resistance. A: In Calu-3
monolayers, apical quinine (1 mg/mL) increased the monolayer permeability (19.4±3.4 μA/cm2, as also shown in Fig. 1A, ⁎ pb0.001 compared with untreated
controls, n=16, ±SEM) in the presence of a Cl− secretory gradient (low Cl− on mucosal surface) and was only partially blocked by the addition of glybenclamide
(change of 6.9±1.8 μA/cm2, ⁎⁎ pb0.05 vs. apical quinine, n=16, ±SEM). The effect of quinine applied to the basolateral surface was less pronounced than
apical administration (⁎⁎ pb0.05 vs. apical quinine, n=16, ± SEM). Bumetanide applied to the basolateral surface several minutes after quinine had no effect
compared to apical quinine alone. The change attributable to quinine decreased significantly upon omission of the chloride gradient (‡ pb0.001 vs. apical
quinine in Cl− secretory gradient, n=16, ±SEM). In a reversed chloride gradient, the direction of apparent Cl− movement was reversed (‡‡ pb0.001 vs. apical
quinine in Cl− secretory gradient, n=12, ±SEM). B: In Calu-3 monolayers, apical quinine (1 mg/mL) added in a Cl− secretory gradient caused a decrease in
airway epithelial resistance (⁎ p=0.004, n=16, ±SEM) in Calu-3 cells. C: Quinine (1 mg/mL) had no effect on gross epithelial morphology in Calu-3
monolayers studied for localization of tight junctions (Z0-1, red) and CFTR (green). D: Effects of quinine (1 mg/mL) on Ussing chamber recording and
transepithelial electrical resistance (E) in primary airway surface epithelial cell monolayers (n=8 filters tested, ±SEM).
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Fig. 2 (continued ).
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seen in the chloride secretory configuration, reflecting the
dominant role of the paracellular transport pathway (com-
pared to the transcellular mechanism) at this concentration of
quinine.
3.2. Quinine also inhibits CFTR-dependent transepithelial
short-circuit current
To better discriminate the paracellular vs. transcellular
effects of quinine, we investigated whether concentrations of
apically administered drug that do not disrupt tissue re-
sistance could alter airway epithelial ion movement by an
independent (transcellular) mechanism. Polarizing Calu-3
monolayers treated with quinine at concentrations of 100 μg/
mL showed little activation of chloride dependent junctional
permeability in a gradient directed towards chloride
secretion (Fig. 4, Panel A). Quinine itself at this concentra-
tion also had minimal effect on transepithelial electricalresistance (Fig. 4, Panel B). Although this concentration of
drug had minimal effects on the paracellular pathway, sig-
nificantly reduced transepithelial chloride transport (directly
or indirectly) through a pathway regulated by CFTR was
detected by effects on forskolin (20 μM) activated ISC. This
occurred whether quinine was added before glybenclamide
(44% reduction in ISC, pb0.05, Fig. 4, Panel A) or after
(63% reduction in ISC, pb .001, data not shown), implying
effects on both CFTR dependent and CFTR independent
pathways. A reduced effect was also observed at 10-fold
lower concentrations of quinine (10 μg/ml, 24% reduction
in forskolin mediated Isc when administered prior to
glybenclamide).
4. Discussion
The present findings suggest important effects of quinine
on pulmonary epithelial cells at concentrations that might
occur at both the airway epithelial surface and within serous
}Fig. 3. Influence of 1 mg/ml quinine on transepithelial chloride secretion activated by forskolin. A: Representative ISC tracing. Calu-3 cells initially studied in
Ringers solution followed by 1) mucosal low-Cl− solution, 2) addition of 20 μM forskolin, 3) addition of 1 mg/mL quinine, and 4) addition of 200 μM
glybenclamide. B: After maximal activation of CFTR, addition of high-dose quinine (1 mg/ml) modestly increased apparent ISC in a chloride secretory gradient
(17.0±3.9 μA/cm2, ⁎ pb0.005 compared to forskolin alone, n=18, ±SEM) and was partially inhibited by glybenclamide (⁎ pb0.005, n=18, ±SEM). The
apparent reversal of ISC due to quinine in a reversed chloride gradient is attributable to increased paracellular permeability (⁎ pb0.001, n=14, ±SEM).
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Concentrations of quinine similar to those tested here have
been administered to several hundred human CF subjects in
recent therapeutic trials as a taste-masking agent [4,8–10].
Administration of quinine at 1 mg/ml to either Calu-3
monolayers or primary human airway epithelium disrupts
transepithelial electrical resistance and establishes a para-
cellular chloride transport pathway dependent on the
chloride gradient. Lower doses of quinine (10 and 100 μg/
ml) had minimal effects on TER but blocked transepithelial
chloride dependent ISC through a CFTR-dependent mecha-
nism. Effects such as these were noted for at least 40 min
(Figs. 1 2 3); in unpublished studies, duration of activity
lasting over 3 h has been observed in the Ussing chamber
system.
Quinine is typically aerosolized at concentrations of
0.25 mg/ml, and administered in doses of 1–1.25 mg two to
four times daily [5,6,9]. The concentration of quinine ex-
posed to the surface of airway cells in vivo has not been
measured, and is likely to vary depending on the particular
pulmonary milieu. Despite this, it seems reasonable to
imagine that aerosol droplets might deposit quinine at or nearthis concentration within non-obstructed airway surfaces. It
could also be argued that hyperabsorption of fluid and
electrolytes suggested previously in CF airways might have
concentrating effects on small molecules delivered to
the periciliary layer. Estimates of total airway surface liquid
(2–3 ml in the conducting, proximal airways) suggest that a
regimen of 1.25 mg quinine nebulized twice daily would
deliver substantial amounts of the compound to surface
epithelial cells, in the same way that aerosols of other small
molecules (hypertonic sodium chloride, amiloride and
analogues, chloride secretagogues, tobramycin) have been
achieved at relatively high concentrations to the mucosal
surfaces of CF lungs in the past.
Quinine has known inhibitory effects on calcium activated
potassium channels in human cardiac tissue, animal models
of colonic epithelium, and a number of other cell types
[13,17–19]. The results presented in this study establish that
quinine also causes pronounced alterations of ion permeabil-
ity across airway epithelium, and these effects exhibit dose-
dependence. Aerosolization would be expected to deposit
variable concentrations of quinine in specific regions of the
lung (e.g. large airways, small airways, terminal bronchioles,
Fig. 4. Quinine blocks CFTR dependent Cl− secretion at concentrations that do not alter airway epithelial resistance. A: In the presence of a Cl− gradient, apical
quinine added at 100 μg/mL led to a modest change (7.4 μA/cm2) in ISC. After activation of CFTR with forskolin (20 μM), substantial reduction in short-circuit
current was seen with apical quinine (100 μg/mL, ⁎ pb0.05, n=12, ±SEM). Addition of glybenclamide (Glyb, 200 μM) further reduced ISC (⁎⁎ pb0.005,
n=12, ±SEM). In a reversed Cl− gradient, low dose quinine by itself had minimal effect (−5.8 μA/cm2, n=13, ±SEM), indicating functionally intact junctional
complexes. B: No significant change in monolayer resistance was observed with 100 μg/mL quinine (n=12, ±SEM).
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transepithelial chloride secretion and/or TER might be a
concern in human subjects. In either case, the failure of
forskolin to activate Isc following quinine administration
(Fig. 3) suggests increased junctional permeability estab-
lished by the compound. Under these conditions, paracellular
permeability may undermine the ability to generate vectoral
chloride transport through CFTR or other pathways by
dissipating the necessary gradients.
Agents that alter TER may have important biologic ef-
fects. For example, azithromycin, a compound shown to
improve lung function in CF clinical trials, increases TER
and alters the expression of various tight junction proteins in
vitro [20]. The relationship between tight junction assembly
and function (including ion transport regulation) is complex.
Disruption of tight junctions without gross abnormalities in
structural components (e.g. Fig. 2C) has been described
previously [21,22], and typically reflects permeability to ions
but not proteins or other macromolecules. Ion selectivity of
the paracellular pathway is sensitive to small changes in tight
junction protein expression (e.g. claudins) without producing
gross changes in epithelial structure/function [23–26]. Theeffects of protein expression vary among particular epithelial
tissues. For example, expression of claudin−4 increases TER
in Madin–Darby canine kidney II and LLC-PK1 cells, but
increases Na permeability only in the former cell type [25].
Whether the acute effects of quinine on TER are explained
by changes in tight junction protein assembly in human
airway cells deserves further study.
No direct effect of quinine on single CFTR channels
has been reported previously. If quinine blocked potassium
channels present at the basolateral surfaces of airway epi-
thelium, chloride entry (which occurs in exchange for K+
exit through Na/K/2Cl− co-transporters) would be impaired.
Devor et al. have previously shown the existence of a quinine
sensitive basolateral K+ conductance in human bronchial
epithelial cells [12]. In contrast, the outwardly rectified
chloride channel (ORCC) present in a variety of epithelial
tissues (including those derived from lungs) can be blocked
by quinine [14]. Because CFTR dependent chloride secre-
tion recruits ORCCs, effects of quinine in the present ex-
periments might be attributable to blocked transepithelial
chloride secretion through this ion channel [27]. Further
studies, including direct measurements of quinine on single
358 E. Bates et al. / Journal of Cystic Fibrosis 6 (2007) 351–359CFTR chloride channels, will be necessary to distinguish
these possibilities.
The present study is germane to CF clinical trials that
support the use of aerosolized tobramycin [4,9,28], and more
recently hypertonic saline [5,6]. While the results presented
here raise concern regarding the use of quinine as a taste-
masking agent in CF trials, the Calu-3 model obviously
cannot replicate many aspects of the in vivo situation.
Despite the potential effects of quinine on human airways,
we do not believe our findings alter the interpretation of
recent phase III trials utilizing quinine. For example, because
the majority of patients enrolled in phase III testing of in-
haled tobramycin were homozygous for ΔF508 CFTR (a
mutation that confers defective protein processing), minimal
CFTR would be expected at the cell surface in these subjects.
Although it remains possible that partial function of the
ΔF508 mutation (or other compensatory chloride secretory
channels) might be inhibited by quinine, direct effects of the
drug on CFTR are likely negligible. In trials evaluating
hypertonic saline aerosols, both the control and experimental
arms were administered quinine. Therefore, even if CFTR
mediated ion transport were blunted, a significant therapeutic
benefit could still be discerned.
Because quinine influences the fundamental patho-
physiologic defect in cystic fibrosis (transepithelial chloride
secretion) in vitro, alternatives should be considered in
future, placebo-controlled CF interventional trials. This may
be particularly important in studies evaluating new agents
(so called ‘potentiators’) that restore activity to mutant CFTR
located at the cell surface (e.g. Class III, IV, and VI CFTR
mutations). Compounds such as these are expected to begin
human clinical testing in the very near future [1]. Moreover,
since elements of gustatory sensation are mediated by
mechanisms that rely on ion transport, compounds to mask
taste in CF should be selected with particular attention to
effects on epithelial chloride secretion and/or junctional
permeability. The finding that quinine decreases resistance at
moderate to high doses also raises the possibility of injury to
airway epithelial cells, including disruption of the tight
junctions and other structures crucial to pulmonary mucosal
integrity. This could predispose to infection or impair normal
mucosal defense against the pathogens that chronically
persist in CF lungs.
In summary, we found that quinine has important effects
on airway epithelia at doses expected to be encountered after
aerosolizion of this agent as a taste-masking placebo. The
present findings should be confirmed in vivo, and considered
in the design of placebo controlled trials for cystic fibrosis
and other pulmonary diseases in the future.
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